Troy– Author –
-
Epigenome Editing of Human Hematopoietic Stem Cells Achieves Sustained and Reversible Thrombosis Prevention
preLights (The Company of Biologists) Unknown Overview A groundbreaking study demonstrated that epigenome editing of human hematopoietic stem cells (HSCs) enables sustained and reversible thrombosis prevention. This innovative technology... -
Voyager Therapeutics Advances Two Tau-Targeted Alzheimer’s Therapies Towards Key Clinical Milestones
NeurologyLive USA Overview Voyager Therapeutics announced its progression of two innovative therapeutic candidates targeting tau protein, a key pathological hallmark of Alzheimer's disease, toward significant clinical milestones. These c... -
IPS HEART Secures FDA Rare Pediatric Disease Designation for Muscular Dystrophy-Associated Cardiomyopathies, Accelerating Cardiac Regenerative Medicine Development
BioSpace USA Overview IPS HEART has received Rare Pediatric Disease Designation (RPDD) from the U.S. FDA for its iPSC-derived therapeutic candidate for muscular dystrophy-associated cardiomyopathies. This marks the company's 8th FDA regu... -
In Vivo CAR-T Cell Therapy Achieves Clinical Proof of Concept; AI Integration Poised to Revolutionize Cancer Treatment
OncoDaily Unknown Overview In vivo CAR-T cell therapy has achieved initial clinical proof of concept, demonstrating its potential to transform cancer treatment. This novel approach directly delivers and expresses CAR genes in T-cells wit... -
CEA-Targeted CAR-NK Cells Derived from iPSCs Demonstrate Potent Anti-Tumor Activity Against Colorectal Cancer
Frontiers in Immunology Unknown Overview A new study reports that chimeric antigen receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) exhibit potent anti-tumor activity against colorectal cancer. These CEA-target... -
Texas Children’s Hospital Establishes Cell and Gene Therapy Innovation Hub to Accelerate Development and Expand Access
Texas Children's Hospital USA Overview Texas Children's Hospital has established a new innovation hub to accelerate breakthroughs in cell and gene therapy (CGT). This comprehensive facility centralizes all necessary resources and experti... -
CGT Manufacturers Transform Regulatory Demands into Innovation Drivers: New Strategies for Enhanced Quality and Efficiency
MasterControl USA Overview Cell and gene therapy (CGT) manufacturers are adopting new strategies to leverage stringent regulatory requirements as opportunities for innovation and quality improvement, rather than mere obstacles. Central t... -
RiboX Therapeutics Receives FDA IND Clearance for RXIM002, the First Circular RNA-Based In Vivo CAR Therapy for Autoimmune Cytopenias
BioSpace USA Overview RiboX Therapeutics has received FDA Investigational New Drug (IND) clearance for RXIM002, a circular RNA (circRNA)-based in vivo CAR therapy targeting autoimmune cytopenias. RXIM002 is the first in vivo CAR therapy ... -
RegMedNet Highlights Specialized Partnerships to Overcome Cell Therapy Challenges: New Strategies for Accelerated Commercialization
RegMedNet Unknown Overview RegMedNet's latest 'Cell Therapy Weekly' edition spotlights emerging specialized partnerships aimed at resolving critical challenges in the cell therapy sector. These collaborations focus on streamlining comple... -
CDMO Capacity Crunch Persists in Cell and Gene Therapy Sector: Strategic Partnerships Crucial for Accelerating Innovation
Contract Pharma USA Overview The cell and gene therapy (CGT) sector faces a severe and persistent capacity crunch among Contract Development and Manufacturing Organizations (CDMOs), driven by soaring demand. This bottleneck significantly...
